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In 2010, we published an initial point-counterpoint on laboratory diagnosis of C. difficile 30 
infection (CDI).  At that time, nucleic acid amplification tests (NAATs) were just becoming 31 
commercially available, and the idea of algorithmic approaches to CDI was being explored.  32 
Now there are numerous NAATs in the marketplace and based on recent proficiency test 33 
surveys, they have become the predominant method used for CDI diagnosis in the United States.  34 
At the same time, there is a body of literature that suggests that NAATs lack clinical specificity 35 
and thus inflate CDI rates.  Hospital administrators are taking note of institutional CDI rates 36 
because they are publicly reported.  They have become an important metric impacting hospital 37 
safety ratings and value-based purchasing where hospitals may have millions of dollar of 38 
reimbursement at risk.  In this point-counterpoint using a Frequently Asked Question approach, 39 
Ferric Fang of the University of Washington, who has been a consistent advocate for NAAT-40 
only approach for CDI diagnosis, will discuss the value of a NAAT-only approach, while 41 
Christopher Polage of the University of California-Davis and Mark Wilcox of Leeds University, 42 
UK, who have each recently written important articles on the value of toxin detection in the 43 




























Frequently Asked Questions 47 
1. Why is there so much controversy about the performance of C. difficile diagnostic tests?   48 
Fang- Diagnostic tests detect either toxigenic C. difficile or its toxins.  Many labs have switched 49 
from toxin assays to NAATs that detect toxigenic C. difficile in order to maximize 50 
sensitivity, as toxin assays were previously missing cases of clinically significant CDI.  51 
However some recent studies have highlighted that NAATs can be positive in colonized 52 
patients without disease, and patients with positive toxin assays may have a worse prognosis 53 
than those with a positive NAAT only (1, 2).  This has renewed controversy about the 54 
optimal approach to diagnosis CDI. 55 
Polage and Wilcox- The performance of C. difficile diagnostic tests is controversial for 4 56 
reasons: 57 
1) There is no reliable clinical or laboratory definition for CDI that accurately distinguishes true 58 
CDI from non-CDI-related symptoms in all patients (3). Most diarrhea in hospitals is not due 59 
to CDI and virtually all clinical signs and symptoms of CDI are non-specific and occur 60 
commonly in patients without CDI (4, 5). Asymptomatic C. difficile colonization is also 61 
common in hospitals, particularly among patients who get selected for C. difficile testing due 62 
to shared risk factors between colonization and CDI (6, 7). Thus, the positive predictive 63 
value of detecting toxigenic C. difficile in routine diarrheal samples submitted to the 64 
laboratory is low and insufficient to diagnose CDI (1-3, 7).  65 
2) The measured performance of C. difficile diagnostic tests is highly dependent on the 66 
definition of CDI and ratio of CDI to colonization in the population being tested (2, 3, 8). For 67 
example, toxin tests are sensitive (and agreement with toxigenic culture is high) in patients 68 
with pseudomembranous colitis due to the high ratio of CDI to colonization in this 69 
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population (8). Conversely, toxin tests appear less sensitive in routine stool samples 70 
submitted to the laboratory due to frequent overlap of non-CDI diarrhea with C. difficile 71 
colonization and the lower ratio of CDI to colonization in this population (1-3, 8,9).  72 
3) Anecdotal experiences with cases of severe CDI missed by toxin tests have promoted a desire 73 
for absolute sensitivity regardless of specificity and an erroneous belief that all patients with 74 
toxigenic C. difficile and diarrhea have CDI as the cause of their symptoms (9-14). 75 
Widespread misclassification of non-CDI diarrhea in patients with C. difficile colonization as 76 
‘CDI’ has reinforced the belief that toxin tests are insensitive for CDI without systematic 77 
investigation to verify the true frequency of disease (2, 9, 11, 15-17). 78 
4) C. difficile tests vary in performance accuracy, including those with the same target; for 79 
example, there are marked and sometimes significant differences in sensitivity and specificity 80 
between commercial toxin detection tests (1, 3, 9). Thus, use of less well performing tests 81 
can reinforce perceptions driven by other factors (above). 82 
Editor’s comment: The measured accuracy of any diagnostic test is dependent upon the 83 
reference test to which the diagnostic test is being compared.  The American Society for 84 
Microbiology has a group that is currently working on an evidence based practice guideline for 85 
laboratory detection of C. difficile infection.  There are over 15 different reference methods that 86 
have appeared in this literature some of which are clearly biased.  This lack of a standard 87 
reference method to define C. difficile infection clearly complicates an already very complicated 88 
literature and there is no consensus in sight.   89 
 90 
2. What are the effects of using nucleic acid amplification testing for C. difficile on C. 91 
difficile infection data that institutions report to public health authorities?   92 
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Fang- Since NAATs are more sensitive than toxin assays, the introduction of a NAAT will 93 
initially increase the apparent infection rate at an institution.  However, this is mitigated by 94 
two factors.  First, the National Health Safety Network applies a correction factor for 95 
institutions that use NAATs to diagnosis CDI, so that institutions using more sensitive 96 
diagnostic methods will not be penalized (18).  Second, the greater detection of toxigenic C. 97 
difficile by NAATs can facilitate more effective infection control measures so that 98 
institutional infection rates subsequently decline (19-21).  This has been the experience at my 99 
own institution, where several years ago our CDI rates fell within a few months of 100 
introducing NAAT and have remained low ever since.  The sensitive detection of toxigenic 101 
C. difficile can facilitate efforts to reduce institutional transmission.  That said, public health 102 
agencies must recognize that laboratory data alone cannot be used to accurately monitor CDI 103 
rates, as laboratory tests detect both colonized and infected patients. 104 
Polage and Wilcox- When positive laboratory test results are used as the sole measure of 105 
healthcare facility-onset CDI – as is currently the case for most hospitals in the United States 106 
– NAAT-based CDI diagnosis can have a dramatic effect on the number of CDI cases 107 
institutions report publically and affect hospital reimbursement under value-based payment 108 
programs (18, 22-24). This is because NAAT-based CDI testing results in public reporting of 109 
all fecal toxin-negative samples with toxigenic C. difficile as positive regardless of clinical 110 
disease or treatment. Most hospitals using NAAT or GDH immunoassay plus NAAT for CDI 111 
diagnosis see an increase in the number of ‘CDI cases’ reported publically by 1.5 to 3-fold 112 
over rates derived from toxin tests (18, 23, 24). The NAAT-related increase is partially 113 
accounted for by an adjustment in the NHSN standardized infection ratio (SIR) calculation 114 
used to compare hospital performance, but the current adjustment does not fully correct for 115 
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the increased number of positive results at all hospitals (24). This might be appropriate if all 116 
toxin-negative patients with C. difficile detected by NAAT had CDI clinically, but this is not 117 
the case (2, 3, 8). Recent outcome studies show that most toxin-negative patients with C. 118 
difficile detected by NAAT or culture recover spontaneously without treatment and have a 119 
significantly lower rate of adverse events than toxin-positive patients; furthermore, the 120 
duration of symptoms for toxin-negative patients with C. difficile detected by NAAT is 121 
similar to that for C. difficile-negative control patients (1, 2, 25). These findings suggest that 122 
using NAAT as a standalone test for CDI diagnosis results in a considerable amount of over-123 
diagnosis that has important clinical, financial, and reputational implications for hospitals (2, 124 
25). For this reason, guidelines in the UK and Europe now recommend toxin testing to 125 
confirm CDI in NAAT-positive patients, and consideration of other causes for symptoms 126 
before diagnosis and treatment of CDI in toxin-negative patients (3). 127 
 128 
3. Should GDH immunoassays be used as a screening test to determine which stool 129 
specimens should be subjected to toxin or nucleic acid amplification testing for C. 130 
difficile?   131 
Fang- GDH immunoassays are more sensitive than toxin assays and can be used to screen 132 
specimens for the presence of C. difficile (26).  However GDH is expressed by both toxigenic 133 
and non-toxigenic strains of C. difficile, so GDH-positive specimens must be further tested 134 
using NAAT and/or toxin assays.  Such an approach is less expensive than performing 135 
NAAT on all specimens but is also less sensitive, particularly for non-027 strains (27, 28).  136 
This is not because of strain-dependent differences in GDH expression but most likely 137 
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because 027 strains tend to attain higher organism burdens.  The calculated sensitivity of the 138 
GDH immunoassay is dependent on the sensitivity of the comparator method, and studies 139 
including a blinded multi-center trial using the most sensitive comparators (NAAT and 140 
toxigenic culture with detection of both spores and vegetative cells) have shown that GDH 141 
assays miss approximately 20% of specimens detected by NAAT in patients with 142 
symptomatic CDI (17, 27, 28).  In short, a GDH-based algorithm is less costly but sacrifices 143 
sensitivity. 144 
Polage and Wilcox- GDH detection is sensitive for CDI because C. difficile vegetative cells 145 
express and secrete GDH extracellularly, and GDH may play a role in C. difficile 146 
colonization in vivo (29). As a result, most clinical samples with toxigenic C. difficile 147 
detectable by culture or NAAT are positive by GDH immunoassays and virtually all samples 148 
with toxins detectable are positive for GDH (3, 9, 30).  The occasional samples that are 149 
positive by NAAT but negative for GDH have a low concentration of C. difficile and no 150 
toxins, suggesting that these are most likely C. difficile carriers or patients on treatment (30). 151 
Most laboratory comparisons find that GDH immunoassays are >90% sensitive for C. 152 
difficile, as confirmed by two meta-analyses; a few studies report slightly lower sensitivities 153 
in the range of 83.1-87.6% (3, 9, 26).  In the most recent meta-analysis, the pooled sensitivity 154 
of GDH immunoassays was 94% (95% CI, 89-97%) and 96% (95% CI, 86-99%) relative to 155 
cell cytotoxin neutralization assay and toxigenic culture, respectively; the pooled specificity 156 
was 90-96% (3). Finally, recent studies showed that GDH expression is a reliable 157 
characteristic of all common C. difficile strains, contradicting an earlier study, which 158 
hypothesized that differential GDH expression might explain the lower sensitivity of two-159 
step immunoassay algorithms for some C. difficile ribotypes (9, 27). In summary, GDH 160 
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immunoassays are less expensive and modestly less sensitive as a screening test than some 161 
NAAT; NAAT are generally more sensitive, specific, and expensive. Samples that test 162 
positive by either method should be retested by a fecal toxin A/B immunoassay to confirm 163 
clinical CDI disease (3). Individual laboratories should choose the C. difficile screening test 164 
and algorithm that works best in their lab and institution. 165 
 166 
4. What is the most cost-effective strategy for C. difficile diagnosis?   167 
Fang- Although immunoassay methods are less costly for the laboratory than NAATs, a recent 168 
cost-effectiveness analysis has determined that NAAT is the most cost-effective approach 169 
from an institutional standpoint due to the $9,000 to $13,000 cost of each missed case of CDI 170 
(31).  Another study found that patients diagnosed with CDI by NAAT had a two-day shorter 171 
median length of stay compared to patients diagnosed by toxin immunoassay, even though 172 
the patients did not differ with regard to co-morbidity, prior hospitalizations, laboratory 173 
parameters or mortality (32).  Length of stay is an important contributor to the financial costs 174 
of CDI (33, 34), and the authors suggested that the sensitive NAAT assay might result in 175 
more timely diagnosis and treatment (32).  In addition, reliance on a less sensitive diagnostic 176 
method may lead to more empiric therapy (35) and repeat laboratory testing, because 177 
clinicians lack confidence in a negative result.  Thus, the use of NAAT can promote 178 
responsible antimicrobial stewardship and reduce unnecessary antibiotic and laboratory 179 
utilization. 180 
Polage and Wilcox- The latest guidelines recommend a two or three-step algorithm as the most 181 
effective strategy to diagnose CDI and minimize over-diagnosis of C. difficile colonized 182 
individuals who have other causes of their diarrheal symptoms (3). The algorithm should 183 
 on F
























start with a rapid and sensitive screening test with high negative predictive value for CDI, 184 
such as a GDH immunoassay or NAAT, to minimize empiric isolation and treatment of non-185 
CDI patients (3). Samples with a positive screening test should be retested with a toxin A/B 186 
immunoassay to identify patients with toxins, who have the highest likelihood of CDI 187 
clinically and need for treatment (3).  Patients with toxigenic C. difficile but no fecal toxins 188 
need additional clinical evaluation to distinguish incidental C. difficile colonization (most 189 
patients) from CDI with a negative toxin test (fewer patients) (3). The overall sensitivity and 190 
specificity of this approach was verified in a multicenter prospective study in the UK and 191 
supported in a recent meta-analysis (1, 3). The emphasis on fecal toxin detection in this 192 
algorithm to identify patients with high (toxin-positive patients) and low (toxin-negative 193 
patients) likelihoods of clinical CDI disease is supported by outcome studies in multiple 194 
countries (1, 2, 8, 25). In terms of cost, new economic models are needed to determine which 195 
strategy is best since previous models inappropriately assumed that patients with toxigenic C. 196 
difficile and negative toxin tests had CDI and overlooked the costs of CDI over-diagnosis, 197 
including decreased hospital reimbursement (31, 36). 198 
Editor’s comment:  A March 2016 survey of 70 members of Clinmicronet, a global list serve of 199 
doctoral clinical microbiologists showed that 55 laboratories used a NAAT only approach 200 
while 9 used a GDH/toxin screen with PCR confirmation for GDH/toxin discrepant 201 
specimens.   CAP surveys of C. difficile testing also show a preponderance of laboratories 202 
using a NAAT only approach.  Only 6 of 70 respondents used the algorithm of a GDH or 203 
NAAT screen with toxin confirmation of screen positive results described by Polage and 204 
Wilcox. Three laboratories were considering changing to this approach.  One microbiologist 205 
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commented that the decision to change to this algorithm was driven by hospital 206 
administration belief that using this approach would reduce reported CDI rates.     207 
 208 
5. Why do studies of symptoms and clinical outcomes in patients who have C. 209 
difficile DNA or bacteria but not toxins in stool reach such different conclusions?   210 
Fang- NAATs and culture-based methods are more sensitive but less specific, whereas toxin 211 
assays are less sensitive but more specific.  Thus, patient selection is critically important for 212 
the proper interpretation of test results.  With regard to specificity, it is important to 213 
recognize that no C. difficile diagnostic assay is completely specific for clinical disease.  214 
Production of toxin is essential but not sufficient for disease, and even patients with high 215 
fecal toxin levels may be asymptomatic (37, 38), particularly if they have toxin-neutralizing 216 
antibodies (39).  With regard to sensitivity, it is equally important to recognize that toxin 217 
assays can be negative in patients with symptomatic (and even life-threatening) CDI (10, 13, 218 
40, 41).  The insensitivity of toxin assays has been demonstrated even for cases of 219 
pseudomembranous colitis and was a major consideration leading to the development of 220 
more sensitive NAAT assays.  In fact, a false-negative toxin assay is a risk factor for a fatal 221 
outcome in patients with fulminant CDI (10), and I note that one of the toxin-negative 222 
patients in the Polage study (2) "had recurrent CDI as a contributing factor to death."  The 223 
bottom line is that a negative toxin assay cannot rule-out the possibility of CDI.  On the other 224 
hand, the greater sensitivity of NAAT or culture-based diagnostic methods can increase the 225 
likelihood of false-positive results, particularly in patients with a low clinical probability of 226 
C. difficile-associated disease.  Exclusion of patients who fail to meet the clinical definition 227 
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of diarrhea (or have formed stools), are receiving laxatives, or have previously tested 228 
positive, can help to reduce the number of false-positive results.  The best way to avoid false-229 
positive test results is to restrict diagnostic testing to patients who have clinical presentations 230 
consistent with CDI, and inappropriate testing can account for many of the reported instances 231 
of "overdiagnosis" (1, 2).  Institutional guidelines with clear criteria for diagnostic testing can 232 
be helpful in this regard.   233 
Some have advocated the performance of both NAAT and toxin assays to optimize 234 
patient management.  However the data are conflicting.  Although some studies suggest that 235 
patients with positive toxin assays have a worse prognosis than those with positive NAAT 236 
only (1, 2), many other carefully conducted studies involving more than 2,000 patients have 237 
not found toxin assays to be predictive of symptoms, disease severity, mortality, 238 
transmissibility or recurrence (15, 16, 38, 42-44).  In any case, whether the detection of toxin 239 
is indicative of a worse prognosis is beside the point.  The notion that a toxin assay can 240 
distinguish between colonization and infection is fundamentally flawed-- the distinction 241 
between colonization and infection is a clinical one and cannot be based on laboratory 242 
assessment alone.  As Dubberke and Burnham have noted, one must "treat the patient, not the 243 
test" (45).  Some patients with positive toxin assays have asymptomatic colonization (37, 244 
38), and some patients with negative toxin assays have CDI (10, 13, 15, 16, 40-44).  More 245 
than half of patients with symptomatic CDI would be missed by reliance on a toxin 246 
immunoassay (15, 16, 42-44), an unacceptably high proportion of false-negative results.  247 
Furthermore, patients with NAAT-positive/toxin-negative specimens may convert to toxin-248 
positive on re-testing; this was observed in 21% of individuals undergoing re-testing in the 249 
Polage study (2).  I recommend using a negative NAAT to rule-out the possibility of CDI and 250 
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a positive NAAT to indicate the possibility of CDI in a patient with a compatible clinical 251 
presentation; using this approach, toxin assays are unnecessary.  Treatment decisions should 252 
be based on clinical assessment and the presence or absence of toxigenic C. difficile, not on 253 
the ability or failure to detect fecal toxin.   254 
I feel compelled to point out a self-contradiction in the European guidelines that advocate 255 
toxin testing.  On one hand the guidelines acknowledge that "the decision to treat CDI is 256 
ultimately a clinical decision. . . treatment should not be withheld on the basis of laboratory 257 
tests alone"-- but on the other hand, they state that "using NAAT as a stand-alone test and 258 
relying on clinical symptoms to discern patients from CDI from asymptomatic carriers is not 259 
an optimal approach. . . samples with a positive result should be tested further with a toxin 260 
EIA" (3).  On what should treatment decisions be based, clinical assessment or the presence 261 
of toxin?  No wonder clinicians are confused. 262 
  I strongly disagree with the suggestion that a negative toxin assay means that a patient is 263 
only colonized and not infected (1); such a simplistic approach is likely to result in the under-264 
diagnosis of CDI and harm to patients.  Although some suggest that symptomatic patients 265 
with CDI and negative toxin assays have self-limited disease that will resolve without 266 
treatment (1, 2), this cannot be concluded from the available studies, as many of the patients 267 
in these studies who had negative toxin assays received empiric treatment for CDI.  268 
Furthermore, important clinical endpoints other than mortality, such as the duration and 269 
severity of symptoms, were not measured, and the length-of-stay for culture-positive/toxin-270 
negative patients was actually significantly longer compared to controls with both tests 271 
negative (1).  Quite simply, the safety of withholding antimicrobial treatment from 272 
symptomatic patients with positive NAAT and negative toxin assay results has not been 273 
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established.  Untreated patients will also continue to shed C. difficile with the potential to 274 
transmit infection to others, in contrast to those receiving specific antimicrobial treatment 275 
(46). 276 
Polage and Wilcox- There is a growing consensus that most patients with C. difficile DNA or 277 
bacteria but no fecal toxins (i.e., toxin-negative/C. difficile-positive) are clinically distinct 278 
from toxin-positive patients, have better outcomes, and generally do not have CDI as a cause 279 
of their symptoms (1-3, 25). Overall, 14 of 18 studies (78%) have reported a clinical 280 
symptom or outcome difference in toxin-negative/C. difficile-positive patients and large 281 
studies from multiple countries have found less severe disease, a shorter duration of diarrhea, 282 
fewer CDI-related complications, and/or lower mortality in these patients (1, 2, 8, 11, 15-17, 283 
25, 43, 44, 47-54). In several studies, outcomes were similar to negative controls despite 284 
delayed or non-reporting of NAAT or culture results and delayed or no treatment for CDI, 285 
further supporting an alternate cause of symptoms (not CDI) (1, 2, 8, 47, 53).  286 
  Nonetheless, some studies reach the opposite conclusion - that toxin-negative/C. difficile-287 
positive patients have CDI and are not different from toxin-positive patients - and it is 288 
important to understand how and why this might occur (11, 15-17, 43, 49). Most of these 289 
studies were not adequately designed or powered to detect a statistical difference in rare 290 
clinical outcomes, such as CDI-related complications or mortality and erroneously interpret a 291 
non-significant P-value as evidence that differences do not exist (a type II statistical error) 292 
(11, 15-17, 49). Many of these studies also have significant sources of bias, which likely 293 
contributed to the authors’ conclusions, including clinical reporting or reviewer knowledge of 294 
NAAT results, and automatic classification of patients with positive NAAT or culture as 295 
having CDI regardless of disease status (11, 15-17, 43, 49). Another common problem is 296 
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failure to acknowledge that many clinical signs and outcomes seen in patients tested for CDI 297 
are common and non-specific in hospitals, and so are not necessarily indicative of, or related 298 
to CDI (e.g., diarrhea, leukocytosis, ICU care) (11, 16, 49). Pre-analytic issues can also cause 299 
negative results. One study routinely placed fecal samples in Cary-Blair transport media 300 
before toxin testing, making it likely that pre-analytic dilution contributed to negative toxin 301 
EIA results and so masked the relationship between fecal toxins and CDI-related outcomes 302 
(43). In summary, there are good explanations for why some studies fail to find differences 303 
between toxin-positive and toxin-negative/C. difficile-positive patients, and understanding 304 
how and why such misinterpretations occur is critical to interpreting the literature in this 305 
controversial field. 306 
Editor’s comment: Because of the uncertainty of which testing approach is most accurate in 307 
predicting that a patient has CDI, it is clear that pre-analytic considerations are essential in 308 
determining who should be tested for CDI.  Ensuring that tested patients have documented 309 
diarrheal disease and have not received laxatives in the past 48 hours is essential for 310 
diagnostic accuracy regardless of testing approach.   311 
 312 
6. Will increasing the sensitivity of assays for C. difficile toxins in stool increase the 313 
accuracy of toxin assays?   314 
Fang- Not necessarily.  Toxin assays with increased sensitivity may reduce the incidence of 315 
false-negative results.  However, C. difficile toxins are labile at body temperature and 316 
susceptible to inactivation by digestive enzymes (55, 56), so a completely sensitive toxin-317 
based assay may not be feasible.  Even recent "ultra-sensitive" toxin assays are still less 318 
sensitive than NAATs (57).  The likelihood of clinical illness in individuals with positive 319 
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NAAT and negative ultra-sensitive toxin assay results remains to be determined.  It should 320 
also be noted that improvements in the sensitivity of toxin assays will not solve the issue of 321 
false-positive results (i.e., specificity), which can be seen with any C. difficile diagnostic 322 
method. 323 
Polage and Wilcox- Maybe. Higher sensitivity toxin assays will decrease the number of CDI 324 
cases ‘missed’ by toxin tests and bring the analytical and clinical performance closer to the 325 
traditional cell cytotoxin neutralization assay (2, 30, 57, 58). This should be a good thing. 326 
However, lowering the threshold for positive results will also decrease the specificity for CDI 327 
and lead to classifying patients with transient or low levels of toxin due to C. difficile 328 
colonization and antibiotic exposure as (likely erroneously) having disease (2, 57, 58). It is 329 
not known whether detecting and treating these additional patients ‘labelled’ as having CDI 330 
is necessary or beneficial (or possibly harmful) since most resolve their symptoms with 331 
minimal or no treatment (2). These issues could be addressed by quantifying the level of 332 
toxins to help physicians determine the likelihood that each patient has disease and warrants 333 
treatment (57, 58). In any case, the overall diagnostic accuracy will depend on the test 334 
performance characteristics in the population being tested. Test performance and diagnostic 335 
accuracy are affected by many factors including local testing practices, use of diarrheagenic 336 
medications, and the prevalence of CDI, C. difficile carriage, non-CDI diarrhea, anti-toxin 337 
antibodies, and individual C. difficile strains in the population (5, 7, 59). Thus, high-338 
sensitivity toxin tests will probably improve diagnostic accuracy in hospitals/units with good 339 
C. difficile testing practices, a low prevalence of C. difficile carriage, and low prevalence of 340 
non-CDI diarrhea. However, diagnostic accuracy could easily be worse in hospitals/units 341 
with indiscriminant C. difficile testing and a high prevalence of C. difficile carriage and non-342 
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CDI diarrhea. Overall, accurate diagnosis of CDI depends on a multitude of factors and starts 343 
at the bedside with good clinical evaluation of the likelihood of CDI and non-CDI diarrhea 344 
and appropriate sampling and testing. Having a high sensitivity toxin test will definitely be 345 
an improvement, but will not remove the need for laboratories to work with clinicians and 346 
nurses to optimize clinical evaluation, testing, and diagnosis of symptomatic patients. 347 
 348 
7. Should the diagnostic testing strategy for C. difficile infection be different in oncology, 349 
transplant and other immunocompromised patients?  350 
Fang- Immunocompromised hosts are at increased risk for CDI, and at least some studies 351 
suggest comparable clinical severity of CDI in immunocompromised patients with positive 352 
toxin assays and those with positive NAAT only (15, 49).  However, as I advocate the use of 353 
NAAT to diagnosis CDI in all patients, immunocompromised patients do not require a 354 
special testing approach. 355 
Polage and Wilcox- No. The two-step algorithm recommended in European guidelines is still 356 
preferred in oncology, transplant and immunocompromised patients (3). Moreover, 357 
diagnostic strategies based solely on detection of toxigenic C. difficile (e.g., NAAT only) are 358 
likely to perform worse in these patients due to high rates of treatment-related diarrhea and 359 
C. difficile carriage (5, 60). The lower positive predictive value of detecting toxigenic C. 360 
difficile when diarrheal symptoms occur in these patients reinforces the need for judicious 361 
testing, thoughtful clinical evaluation, and fecal toxin testing to maximize the accuracy of 362 
CDI diagnoses in these groups (3, 5, 60).    363 
 364 
8. What is the significance of asymptomatic carriage of toxigenic C. difficile?   365 
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Fang- Asymptomatic colonized patients are an important source of C. difficile transmission (6, 366 
61) and are at substantially increased personal risk for the eventual development of 367 
symptomatic CDI (62, 63).  Therefore the identification of asymptomatic carriers can 368 
enhance infection control and prevention efforts.  A recent study suggests that detection and 369 
isolation of colonized patients can prevent hospital-acquired CDI (64), and a CDC analysis 370 
has concluded that reduced transmission due to the isolation of carriers was responsible for 371 
the reduction in CDI incidence (65).  High-risk antibiotics (e.g., cephalosporins, 372 
fluoroquinolones, clindamycin) should be avoided if at all possible in patients known to carry 373 
toxigenic C. difficile, and the possibility of CDI should be immediately considered if 374 
diarrhea, fever or other compatible symptoms develop. 375 
Polage and Wilcox- Asymptomatic C. difficile carriers outnumber CDI patients by at least 5 to 1 376 
in most hospitals and are likely to be an important source of nosocomial C. difficile 377 
transmission and infection (6, 7, 62, 64). A few studies have linked asymptomatic carriers to 378 
a third or more of hospital-onset CDI cases (6, 7, 61). These observations have sparked an 379 
interest in screening and isolation of asymptomatic carriers as a strategy to decrease 380 
healthcare-associated CDI (6, 7, 64). So far, a single before-and-after study has been 381 
published with results suggesting that screening may be effective (64). However, the current 382 
absence of proven interventions for asymptomatic colonization and potential ramifications of 383 
isolating large numbers of patients emphasizes the need for larger, well-controlled, multi-384 
center studies to confirm the effectiveness of screening before widespread adoption (7, 64).  385 
  Asymptomatic C. difficile colonization may also be an important predisposing risk factor 386 
for CDI, but the story is somewhat mixed (59, 62, 66). Studies from the 1990s associated 387 
lack of symptoms after C. difficile acquisition with pre-existing anti-toxin antibodies and 388 
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prior asymptomatic C. difficile colonization with lower risk of CDI in hospitals (59, 66). 389 
These studies promoted the belief that most asymptomatic C. difficile carriers were immune 390 
to C. difficile toxins but the high rate of colonization with a non-toxigenic C. difficile strain 391 
(which also protects against CDI) was a potential confounder in one often mentioned review 392 
(59, 66). More recently, asymptomatic C. difficile colonization has been associated with an 393 
increased risk of CDI, but it is unclear if this is an artifact of NAAT testing, a change in the 394 
epidemiology and pathophysiology of CDI, or simply a reflection of differential risk 395 
according to the toxigenic status of colonizing strains (62). Hence, more work is needed to 396 
determine the relationship between asymptomatic C. difficile carriage and subsequent risk of 397 
CDI.  398 
  Finally, as noted above, asymptomatic C. difficile colonization is probably an important 399 
source of erroneous CDI diagnoses in hospitals using C. difficile tests with poor predictive 400 
value for CDI, as colonized patients with diarrheal symptoms due to medications, underlying 401 
disease, and other infectious agents will yield positive (misleading) results (2, 5, 7, 67-69). 402 
 403 
Editor’s comment: One of the ongoing discussions concerning C. difficile is if admission 404 
screening has any benefit.  If asymptomatic patients are found to be colonized, they would 405 
likely to be isolated since there are data suggesting colonized patients may spread C. difficile. 406 
Although limiting the use of “high risk” antimicrobials in colonized patients is an attractive 407 
idea, whether it will reduce CDI infection rates is not understood.  Since treatment does not 408 
reliably clear C. difficile in significant proportion of patients with CDI, antimicrobial 409 
clearance of carriage is also likely to be ineffective as well.     410 
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9. Much of the debate seems to be about the potential for false-positive results for C. 412 
difficile infection. What are the consequences of administering antibiotics to treat C. 413 
difficile infection to  patients who are colonized, but not infected, with C. difficile?   414 
Fang- Administering antibiotics to asymptomatic colonized patients will not provide a clinical 415 
benefit and will disrupt the host microbiota.  The use of unnecessary antibiotics can also 416 
promote the emergence of antibiotic-resistant organisms such as VRE (vancomycin-resistant 417 
enterococci) (70). 418 
Polage and Wilcox- Antibiotic treatment for CDI is not benign. Metronidazole and vancomycin 419 
increase the risk of colonization and infection with multi-drug resistant organisms and 420 
promote rebound overgrowth of C. difficile in colonized patients after antibiotic 421 
discontinuation, which can lead to prolonged shedding or active infection (CDI) (71-73). 422 
Reflexive treatment of patients with false-positive results for CDI can also lead to delayed 423 
recognition of outbreaks (e.g., norovirus) or alternative diagnoses (e.g., medication-induced 424 
diarrhea, ischemic colitis), and treatment failure (67-69). In the near future, antibiotic use in 425 
hospitals will be reported publically and hospitals will be mandated to implement 426 
antimicrobial stewardship programs to improve antibiotic use, creating additional incentives 427 
for hospitals to curb excessive/unnecessary antibiotic use.  Thus, routine administration of 428 
antibiotics to patients with false-positive results for CDI has significant negative 429 
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